Introduction
The small GTPase Ras is commonly mutated in human cancers, often glycine 12 to valine (G12V), to remain in the constitutively active oncogenic GTP bound state (Bos, 1989) . It has long been appreciated that expression of this active version of Ras promotes tumor initiation by activating at least three different effectors based on the work from many labs using Ras effector binding mutants, dominant-negative and constitutively active proteins downstream of Ras, and pharmacological inhibitors: Raf, PI3-kinase (PI3K), and RalGEFs (Shields et al., 2000; Ulku and Der, 2003) . Raf is a serine/threonine kinase that is localized to the plasma membrane from the cytoplasm and activated by GTP-Ras. Activated Raf proteins then initiate a MAP kinase (MAPK) signal transduction cascade that leads to transformed morphologies, anchorage-independent growth, and angiogenesis (Morrison and Cutler, 1997; Shields et al., 2000) . The PI3K is also activated via interaction of the p85 regulatory subunit with GTP-Ras, leading to the phosphorylation of phosphoinositides, creating multiple cascades that lead to changes in cell morphology, as well as fostering angiogenesis and cell survival (Luo et al., 2003) . Lastly, RalGEFs are a family of five guanine exchange factors (GEFs) that are activated via their recruitment to the plasma membrane by GTP-Ras, where they activate RalA and RalB, the former of which appears to be required in tumorigenesis (Feig, 2003; Lim et al., 2005) .
It is well established that Ras promotes the initiation of tumorigenesis. However, patients are diagnosed and treated once tumors have already been established, during what is termed tumor maintenance. In this regard, mice harboring a doxycycline (dox)-inducible oncogenic version of Ras grew tumors (in the absence of the tumor suppressor INK4a) upon ingesting dox, but when these treatments were ceased the tumors regressed (Chin et al., 1999) . It was concluded that tumors become "addicted" to oncogenic Ras, requiring this protein to both initiate and maintain tumor growth (Chin et al., 1999) , as is the case for other oncogenes (Giuriato et al., 2004) .
Despite the fact that oncogenic Ras expression is required during tumor initiation and maintenance, the normal microenvironment for which a tumor initiates is vastly different from that in which a tumor is maintained. In particular, the altered microenvironment of the tumor can play a positive role in tumor growth. The stroma of a tumor is aberrant, having appearances of undergoing a wound healing response (Dvorak, 1986) in which cell proliferation can be stimulated and tumor growth enhanced (Mueller and Fusenig, 2004) . Mast cells are recruited to the tumor and then release metalloproteinases, which in turn free growth and angiogenic factors trapped in the ECM to promote tumor growth and progression (Coussens and Werb, 2002) . The vasculature can supply a host of survival-and growth-promoting factors (Bergers and Benjamin, 2003) . Even the hypoxic environment of tumors can activate the transcription factor HIF-1α, and correspondingly a series of genes to counter hypoxia that are advantageous to the tumor, including those that foster angiogenesis, cell proliferation and survival, and glycolysis, to name a few (Harris, 2002) .
Given that the microenvironment in which tumor cells reside changes as a tumor becomes established, we asked whether Ras exerts its oncogenic effects through the same set of effectors during tumor initiation and maintenance. However, any one of the three major Ras effectors alone can promote tumor initiation and hence presumably tumor maintenance of transformed murine cells (Rangarajan et al., 2004) and, although with different kinetics, also in rat mammary glands in vivo . Indeed, transformation and tumorigenesis are typically more lax in rodent cells than in human cells (Lim and Counter, 2004; Rangarajan and Weinberg, 2003) . We therefore chose to focus our studies on human cells. In this regard, expression of the SV40 viral oncoproteins T-and t-Ag and the mammalian protein hTERT (the catalytic subunit of telomerase) in conjunction with oncogenic (G12V) Ras (Ras
G12V
) drives normal human cells from a wide spectrum of cell types to a tumorigenic state (Hahn et al., 1999; O'Hayer and Counter, 2005) , providing a simplified and defined system to explore Ras oncogenesis in human cells (Hamad et al., 2002) . Using this system, we replaced Ras with different combinations of molecules that activate Ras effector pathways to determine which signals were required to initiate tumor growth and, by generating tumors with an inducible Ras protein, which pathways maintained tumor growth once Ras expression was silenced.
Results and discussion
Multiple Ras effectors are required to initiate tumor growth of human cells in vivo To explore the requirements of oncogenic Ras signaling during the dynamic process of tumorigenesis, we sought to identify the signals activated by oncogenic Ras that are required to initiate versus maintain tumor growth of human cells. To first identify the pathways required for tumor initiation, we replaced oncogenic Ras with molecules that preferentially activate PI3K, MAPK, or RalGEF pathways in primary human embryonic kidney cells engineered to express T-Ag, t-Ag, and hTERT (termed TtH cells). Since tumor growth of TtH cells was already shown to minimally depend upon expression of the E37G mutant of oncogenic Ras (Hamad et al., 2002) , which primarily activates RalGEFs (White et al., 1996) , we tested whether activation of the PI3K pathway, the MAPK pathway, or both cooperate with Ras G12V,E37G to initiate tumor growth. Ras G12V,E37G was stably coexpressed in TtH cells with either a control vector, an activated form of Raf-1 (⌬Raf22W) to stimulate the MAPK pathway (Stanton et al., 1989) , an activated form of PI3K (p110-CAAX) to stimulate the PI3K pathway (Rodriguez-Viciana et al., 1997), or both ⌬Raf22W and p110-CAAX. As further controls, TtH cells harboring vector alone or a vector encoding oncogenic Ras were generated. The resultant six polyclonal cell lines were confirmed to express the desired transgenes ( Figure 1A ) and assayed for activation of the MAPK and PI3K pathways by measuring the levels of phosphorylated ERK1 and 2 (ERK1/2) and phosphorylated AKT, respectively. As expected, ERK1 and ERK2 were specifically activated only in cells expressing
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CANCER CELL : NOVEMBER 2005 ⌬Raf22W, whereas AKT was weakly activated in all cells, apparently due to the leaky nature of the Ras G12V,E37G mutant, although AKT was clearly the most phosphorylated in cells expressing p110-CAAX ( Figure 1B) .
The six cell lines were each injected subcutaneously into four immunocompromised mice, and tumor growth was monitored over time. Only cells in which all three Ras effector pathways were activated were tumorigenic. Specifically, cells coexpressing Ras
G12V,E37G
, ⌬Raf22W, and p110-CAAX were the most aggressive followed by cells coexpressing Ras G12V,E37G and ⌬Raf22W ( Figure 1D ), in which PI3K was weakly activated by the Ras G12V,E37G protein ( Figure 1B) . PI3K activation was shown to be required in the latter cells, as diminishing AKT activation by expression of PTEN, a negative regulator of this pathway (Vivanco and Sawyers, 2002) , abolished the tumorigenic growth of these cells ( Figures 1C and 1D ). Since robust activation of any two of the RalGEF, PI3K, or MAPK pathways failed to initiate tumor growth ( Figure 1D and Hamad et al., 2002) , we conclude that these three effectors are minimally required to initiate human tumor cell growth of TtH cells. In agreement, multiple Ras effectors have been reported to drive a variety of human cells expressing hTERT, T-Ag, and t-Ag to a tumorigenic state (Rangarajan et al., 2004) .
Oncogene addiction in human tumor cells
To determine if Ras was required during tumor maintenance in human cells, a 4-hydroxytamoxifen (4-OHT)-inducible ER: Ras G12V fusion protein (Dajee et al., 2002) comprised of a mutant form of the estrogen receptor ligand binding domain and oncogenic Ras was expressed in TtH cells. As a negative control, TtH cells were stably infected with a control retrovirus, and as a positive control, the cells were stably infected with a retrovirus encoding Ras
G12V
. Like vector control cells, in the absence of the 4-OHT the fusion protein was undetectable and did not stimulate the MAPK, PI3K, or RalGEF pathways, as measured by an increase in AKT and ERK1/2 phosphorylation and the level of GTP bound RalA, respectively (Figures 2A and 3A) . This inability to activate Ras effectors was reflected in assays of Ras oncogenesis. In the absence of 4-OHT, ER: Ras
-TtH cells behaved like vector control cells and failed to grow in soft agar ( Figure 2B and data not shown) or form tumors in mice ( Figure 2C ). Conversely, binding of 4-OHT by the ER portion of the fusion protein relieved this inhibition, resulting in detectable ER:Ras G12V protein that behaved like positive control Ras
, activating Ras effectors (Figures 2A and 3A) and promoting anchorage-independent ( Figure 2B and data not shown) and tumorigenic growth ( Figure 2C ). We next addressed whether Ras was required for tumor maintenance, and here we show that inducible inhibition of ER:Ras G12V after tumors had formed by halting 4-OHT treatments led to tumor regression ( Figure 2C ). Thus, as in murine models (Chin et al., 1999; Tarutani et al., 2003) , human cells become addicted to oncogenic Ras for maintenance of tumorigenic growth.
Activation of the PI3K pathway maintains tumor growth in the absence of oncogenic Ras
We next tested which Ras effector pathway(s) need to be activated to overcome the tumor regression observed upon suppressing ER:Ras G12V expression in established tumors. Two independent approaches were used to preferentially activate one arm of Ras oncogenic signaling in ER:Ras G12V TtH cells: acti- vated effectors ( Figure 3A) or Ras effector mutants ( Figure 3D ). Specifically, Ras G12V,T35S or ⌬Raf22W to activate the MAPK pathway (Stanton et al., 1989; White et al., 1995) , Ras
G12V,Y40C
or p110-CAAX to activate the PI3K pathway (Rodriguez-Viciana et al., 1997), or lastly, Ras G12V,E37G or Rlf-CAAX to activate the RalGEF pathway (White et al., 1996; Wolthuis et al., 1997) was stably expressed in ER:Ras
G12V
-TtH cells, as assessed by immunoblot analysis (Figures 3A and 3D ). In the presence of 4-OHT to activate ER:Ras
, all six cell lines had activated MAPK, PI3K, and RalGEF pathways, as measured by an increase in ERK1/2 and AKT phosphorylation, and RalA-GTP levels, respectively ( Figures 3A and 3D) , and all lines grew in a 3E ). In the absence of 4-OHT, the targeted pathways still remained activated ( Figures 3A and 3D ), but consistent with previous results (Hamad et al., 2002) , only cells with an activated RalGEF pathway could still grow in soft agar (Figures 3B and 3E) . Thus, specific Ras effector pathways can be selectively activated in a background in which Ras expression can be controlled, providing a means to test which Ras effector pathways maintain tumor growth in the absence of oncogenic Ras. These six cell lines and one vector control cell line were each injected into four mice given daily doses of 4-OHT to induce ER:Ras G12V expression until a tumor mass was clearly visible (a diameter of 0.7 cm, approximately the size of a pea). At this point, 4-OHT treatments were ceased to terminate ER:Ras
signaling, and tumor growth was monitored for another w25 days, or until tumors reach a maximum volume of w1500 mm
3
. Within 2 days of halting 4-OHT treatments, tumors in which either the MAPK (Ras G12V,T35S or ⌬Raf22W) or RalGEF (Ras G12V,E37G or Rlf-CAAX) pathways were constitutively activated stopped growing and in some mice actually regressed akin to vector control tumors ( Figures 3C and 3F ). Conversely, tumors composed of cells expressing Ras G12V,Y40C or p110-CAAX that preferentially activated PI3K, but not the RalGEF and MAPK pathways ( Figures 3A and 3D ), continued to grow in the absence of oncogenic Ras ( Figures 3C and 3F ). Activation of the PI3K pathway was not, however, alone sufficient to promote tumor growth, as TtH cells coexpressing ER:Ras
G12V
and p110-CAAX injected into four mice in the absence of 4-OHT were not tumorigenic ( Figure 3C ). Additionally, ER:Ras
-TtH cells expressing p110-CAAX did not acquire mutations that
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G12V
. When such cells were isolated from tumors established after 4-OHT had been removed, recultured under drug selection to kill contaminating murine cells, and injected back into four mice in the absence of 4-OHT treatments, no tumors were detected (data not shown). Lastly, these results were reproducible, not only because activation of the PI3K by two different means maintained tumor growth in the absence of ER:Ras G12V expression ( Figures 3C and 3F ), but also because expression of T-Ag, t-Ag, hTERT, ER:Ras
, and the described activated versions of the three Ras effectors in HEK cells isolated from a completely different donor resulted in identical results, namely that only activation of the PI3K pathway could sustain tumor growth in the absence of ER:Ras G12V (data not shown). We conclude that, while Ras-induced tumor initiation of TtH cells minimally requires the activation of the RalGEF, PI3K, and MAPK pathways ( Figure 1D ), once a tumor is formed the requirement of Ras oncogenic signaling can be reduced to activation of the PI3K pathway (Figure 3) .
Inhibition of the PI3K pathway inhibits tumor maintenance
If activation of the PI3K pathway maintained tumor growth in the absence of oncogenic Ras, we reasoned that blocking the PI3K pathway in established tumors should inhibit tumor maintenance in the presence of Ras. Akin to our approach to inducibly regulate Ras expression, we infected Ras
G12V
-transformed TtH cells with a retrovirus encoding 4-OHT-inducible PTEN:ER, generated by fusing the mutant form of the estrogen receptor ligand binding domain to PTEN, a negative regulator of the PI3K pathway (Vivanco and Sawyers, 2002) . In the absence of the 4-OHT, this fusion protein was nearly undetectable by immunoblot and unable to inhibit the PI3K pathway. Conversely, activation of PI3K by Ras G12V was specifically inhibited in the presence of 4-OHT, as phosphorylation of Akt, but not ERK1/2, was lost ( Figure 4A ).
Having established that PI3K activity could be inducibly inhibited, we injected the resultant cells into ten mice to establish tumors, at which point six mice were treated with 4-OHT to induce PTEN:ER expression and inhibit the PI3K pathway, and as a control, four were left untreated. Tumors in the untreated mice continued to grow unabated, reaching maximum tumor volume 12 days later, whereas tumor growth was greatly inhibited in mice treated with 4-OHT ( Figure 4B ), resulting in visibly stunted tumor growth ( Figure 4C 
PI3K activation is required to maintain growth of cells in an established tumor
It is possible that, in the absence of 4-OHT, ER:Ras G12V weakly activated effectors to levels that were undetectable by measuring AKT and ERK1/2 phosphorylation and RalA-GTP levels, which in turn cooperated with p110-CAAX to foster tumor growth once 4-OHT treatments were halted. To definitively test if autocrine activation of the PI3K pathway is indeed alone sufficient to support tumor growth in the absence of Ras, and does not rely on possible weak activation of other Ras effectors by low levels of ER:Ras
G12V
, we tested whether nonmalignant TtH cells expressing p110-CAAX (but not ER:Ras G12V ) were tumorigenic once tumor growth was initiated by completely different Ras
-expressing TtH cells ( Figure 5A ). Four mice were injected with a mixture of TtH cells stably expressing either Ras G12V (to establish a tumor) or p110-CAAX (and the visual marker LacZ to identify these cells). As a control, we similarly injected four mice each with a mixture of TtH cells expressing Ras G12V and TtH cells coexpressing LacZ and either an empty vector, ⌬Raf22W, to activate the MAPK pathway, or Rlf-CAAX to activate the RalGEF pathway.
The mixture of Ras G12V cells and p110-CAAX cells led to tumors that grew faster than any of the other combinations tested ( Figure 5C ). Moreover, when two tumors were excised and treated with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) to stain LacZ-expressing p110-CAAX cells blue, the tumors exhibited prominent blue staining ( Figure 5B ). To ascertain more accurately the contribution of p110-CAAX cells in the tumor, the two remaining tumors were resected, and individual cultures were established in the presence of drug selection to kill contaminating murine cells and enrich for the injected human cells. Upon treatment of the resultant cultures with X-gal, almost one-quarter of the cells stained strongly for LacZ, with many more being weakly positive (Figure 5B ). This number far exceeds the amount injected, indicat- ing that the p110-CAAX TtH cells proliferated in what could best be described as a parasitic fashion, greatly contributing to the malignant mass of the tumors while on their own remaining unable to initiate tumor growth.
The p110-CAAX cells in the tumors did not acquire any additional changes to allow them to grow in this malignant fashion. Neither the original p110-CAAX/LacZ cells nor those isolated from two different tumors (with Ras-transformed cells removed by drug selection) and reinjected into four mice each formed tumors ( Figure 5C ). Similarly, neither vector control nor those cells with a constitutively active MAPK or RalGEF pathway contributed significantly to the tumors ( Figure 5B ). Thus, in the complete absence of oncogenic Ras, activation of the PI3K pathway, and not other Ras effectors, sustains tumor growth.
Ras effector activation in established tumors
The reduced requirement for Ras oncogenic signaling during tumor maintenance could be due either to a frank lack of any need for MAPK and RalGEF activity, or to Ras-independent stimulation of these pathways once a tumor is established. To address these two possibilities, we first assayed whether tumors maintained by p110-CAAX had activated the MAPK and RalGEF pathways in vivo, despite lacking ER:Ras G12V expression and not activating these pathways in culture. Three different tumors derived from ER:Ras G12V TtH cells expressing p110-CAAX were resected from mice w25 days after 4-OHT treatments were halted, well beyond the point when ER: Ras G12V expression was extinguished in culture after 4-OHT removal, and assayed for ER:Ras G12V expression and activation of PI3K, MAPK, and RalGEF pathways. As expected, ER: Ras G12V was not detected in these tumors, as they were grown in the absence of 4-OHT, and the PI3K pathway was activated (Akt was phosphorylated), owing to ectopic p110-CAAX expression. However, even though ER:Ras G12V was not expressed in these tumors, and these cells did not activate the MAPK or RalGEF pathways in the absence of 4-OHT in culture,
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in the tumors ERK1 and ERK2 were phosphorylated, a measure of MAPK activation, and the levels of RalA-GTP were elevated, a measure of RalGEF activation ( Figure 6A ). Thus, the remaining Ras effector pathways were activated in tumors maintained by PI3K activity in the absence of oncogenic Ras expression. We next addressed whether this activation of MAPK and Ral-GEF was important for tumor maintenance in the absence of oncogenic Ras expression. In the case of the MAPK pathway, Ras
G12V
-transformed TtH cells were infected with a retrovirus encoding 4-OHT-inducible MEK
DN
:ER that we generated by fusing the mutant form of the estrogen receptor ligand binding domain to the K 97 -M dominant-negative (DN) version of MEK1, which is well established to inhibit the MAPK pathway (Mansour et al., 1994) . In the absence of 4-OHT, this fusion protein was modestly expressed, but not at a level to robustly inhibit the MAPK pathway. In the presence of 4-OHT, the protein was abundantly expressed and clearly able to specifically inhibit activation of MAPK pathway by Ras
G12V
, as ERK1/2 phosphorylation was abolished without affecting the level of AKT phosphorylation ( Figure 6B ). The resultant cells were injected into eight mice to establish tumors, after which half the mice were treated with 4-OHT to induce MEK DN :ER expression and inhibit the MAPK pathway, and as a control, half were left untreated. Tumors in untreated mice continued to grow unabated, reaching maximum tumor volume 10 days later, whereas tumor growth was inhibited in mice treated with 4-OHT ( Figure 6E ), resulting in visibly stunted tumor growth ( Figure 6D ).
In the case of the RalGEF pathway, RalA shRNA has been shown to inhibit RalGEF-induced transformation, and in a specific manner, as this effect was rescued by expression of a siRNA-resistant RalA protein (Lim et al., 2005) . To generate an inducible RalA shRNA, Ras
-transformed TtH cells were engineered to express the TET repressor protein, which can be inhibited by the molecule dox. The cells were then infected with a retrovirus encoding RalA shRNA downstream of the TET operator and, when exposed to dox, were shown to have a dose-dependant decrease in endogenous RalA protein levels, as assessed by immunoblot ( Figure 6C) . These cells were then injected into eight mice, allowed to form tumors, and then either treated with dox to induce RalA shRNA or left untreated. In this case, inhibition of the RalGEF pathway actually caused tumor regression in some mice ( Figure 6G ), and resected tumors were substantially reduced in their mass ( Figure 6F ). Thus, activation of the MAPK and RalGEF pathways is still required for tumor maintenance, although this activation is independent of oncogenic Ras.
The PI3K/AKT pathway prevents apoptosis during tumor maintenance While the MAPK and RalGEF pathways can be activated in the absence of oncogenic Ras once a tumor is established, PI3K was the only effector that still had to be activated in an autonomous fashion in tumor cells. We therefore addressed what function of oncogenic Ras was so critical that it could not be lost during tumor maintenance. As a starting point, we compared the effects of the loss of oncogenic Ras in the presence and absence of p110-CAAX on tumor histology. Twelve mice were injected with ER:Ras
-TtH cells expressing either p110-CAAX or no transgene (vector). Tumors were allowed to reach a diameter of 0.7 cm in the presence of 4-OHT, after which these treatments were ceased, and 3, 5, 9, 12, 15, and 20 days later one mouse from each of the two treatment groups was photographed or a tumor was removed and analyzed for apoptosis (TUNEL-positive), cell proliferation (Ki67-positive), and/or general histology (H&E staining). In vector control cells, there was a clear increase in TUNEL-positive (Figure 7A ) cells and a decrease in Ki67-positive ( Figure 7B ) cells at day 5, followed by a dramatic collapse of tumor cellular architecture and appearance of hemorrhagic foci, nuclear and cytoplasmic debris at day 9 ( Figure 7C ), the near complete loss of overall tumor structure at day 15 ( Figure 7D ), and the absence of a visible tumor mass at day 20 ( Figure 7E ). During the same time course, p110-CAAX-expressing tumors continued to grow and did not show these profound changes in tumor histology ( Figures 7A-7E) .
As cellular apoptosis preceded the demise of vector control tumors upon silencing ER:Ras G12V expression, we speculated that the effects of p110-CAAX might be related to promoting cell survival. In agreement with this hypothesis, we show that of two well-established downstream targets of PI3K, the progrowth and survival protein AKT (Vivanco and Sawyers, 2002) , but not Rac, a GTPase that affects the actin cytoskeleton (Burridge and Wennerberg, 2004) , maintained tumor growth in the absence of Ras. Specifically, a constitutively active version of AKT (myr-AKT [Kulik et al., 1997]) or Rac (Rac Q61L [Singh et al., 2004] ) was stably expressed in the ER:Ras
-TtH cells (Figure 7F) , and the resultant cell lines were injected into four mice each treated daily with 4-OHT until tumors were established, after which time these treatments were stopped to terminate the ER:Ras G12V signaling. Cells expressing myr-AKT continued to grow in the absence of oncogenic Ras, whereas those expressing Rac Q61L regressed ( Figure 7G ). The PI3K pathway is negatively regulated by the tumor suppressor PTEN, and PTEN expression is lost in many types of
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cancer cells, leading to AKT activation (Vivanco and Sawyers, 2002) . Thus, as a means to activate the PI3K pathway in a more physiological way, we tested whether downregulation of PTEN could maintain tumor growth in the absence of Ras
G12V
.
ER:Ras
G12V
-TtH cells were stably infected with a retrovirus encoding a PTEN shRNA, which led to a decrease in PTEN protein levels and activation of AKT in the absence of ER:Ras
( Figure 7F ). The resulting population injected into four mice readily formed tumors in mice that continued to grow unabated when oncogenic Ras signaling was silenced by halting 4-OHT treatments ( Figure 7G ). Conversely, tumors derived from control cells expressing a scrambled version of the shRNA that failed to inhibit PTEN expression ( Figure 7F ) regressed upon halting 4-OHT treatments ( Figure 7G ). These effects were limited to tumor maintenance, as ER:Ras
-TtH cells expressing either PTEN shRNA or myr-AKT were not tumorigenic in the absence of 4-OHT (data not shown). We surmise from these G12V shRNA and either a control vector (white triangles) or one encoding p110-CAAX (black triangles) or SW480 cells expressing doxinducible K-Ras G12V shRNA and either a control vector (white squares) or one encoding p110-CAAX (black squares) after dox treatments were initiated (arrow). E: Representative tumors in mice (top, arrow, location of injection) and when resected (bottom) after the described cells were injected in mice treated with dox once tumors were established to inhibit the expression of the K-Ras G12V allele. Tumors were viewed 36 days after dox treatments were begun.
gain-and loss-of-function experiments that, once tumor growth has been initiated, one of the main functions of oncogenic Ras is to protect neoplastic cells from an apoptotic fate by activation of the AKT pathway.
Activation of PI3K is required to maintain growth of human cancer cell lines in the absence of oncogenic Ras
While we demonstrate using multiple assays that genetically engineered human tumor cells depend upon PI3K activation for tumor maintenance, we wished to address if the same holds true in actual cancer cell lines isolated from patients diagnosed with cancer in which Ras mutations are present. Moreover, our studies were performed with H-Ras, whereas most tumors have K-Ras mutations (Bos, 1989) , and H-and K-Ras can activate PI3K pathway to different extents (Yan et al., 1998) . We therefore introduced a dox-inducible shRNA specific for the endogenous oncogenic G12V allele of K-Ras (and the TET repressor protein) into CAPAN-1 and SW480 cells, two cell lines derived from completely different human cancers that are known to express this mutant allele (Brummelkamp et al., 2002; Ikehara et al., 2005) , and showed by immunoblot that addition of dox to the resultant cell lines led to a dose-dependant decrease in endogenous K-Ras protein levels ( Figure 8A ). The ability of this shRNA sequence to suppress oncogenic Ras expression was reflected in assays of Ras oncogenesis, as CAPAN-1 cells engineered to constitutively express the described K-Ras G12V shRNA (and an empty vector) failed to grow in soft agar. Coexpression of a siRNA-resistant K-Ras G12V protein in these cells restored soft agar growth to the level of vector control cells lacking any shRNA sequence ( Figure 8B ), indicating that the effects of the shRNA were a consequence of knocking down K-Ras G12V expression. Similar observations were found in assays of tumor growth. Specifically, tumor initiation of CAPAN-1 and SW480 cells expressing dox-inducible shRNA (and p110-CAAX; see below) in the presence of constant dox treatments was greatly retarded. Again, this reduc-tion in tumor growth was rescued in both cell lines in which the constitutive knockdown of K-Ras G12V was complemented by expression of a siRNA-resistant K-Ras G12V protein ( Figure 8C) . Thus, we demonstrate that endogenous K-Ras G12V can be specifically knocked down in two human cancer cell lines, resulting in a reduction of Ras-mediated transformation and tumorigenesis.
To next test if activation of the PI3K pathway could rescue the loss of Ras function during tumor maintenance, p110-CAAX or a control vector was introduced into the two cell lines engineered to express dox-inducible K-Ras G12V shRNA. The resultant four populations were then each injected into four mice in the absence of dox to allow K-Ras G12V expression and establish tumors. Upon initiation of dox treatments to knock down K-Ras G12V expression, vector control cells began to regress, whereas those tumors expressing p110-CAAX continued to grow ( Figure 8D ), resulting in a clearly visible difference in the tumor size between vector-and p110-CAAX-expressing cells ( Figure 8E ). Activation of the PI3K pathway was not, however, alone sufficient to promote tumor growth in the absence of Ras
G12V
. Tumor initiation was greatly reduced or abolished in the two cell lines harboring dox-inducible K-Ras G12V shRNA and p110-CAAX when injected into mice in the presence of dox (to constitutively inhibit K-Ras G12V expression), and in the cases where tumors masses were detected, the tumors grew extremely poorly ( Figure 8C ). Thus, activation of the PI3K pathway maintained the tumorigenic growth of not only engineered tumor cells in the absence of Ras, but also human cancer cell lines.
Reduction in the requirements of oncogenic Ras during tumorigenesis
Tumorigenesis is a dynamic process, and hence we addressed whether Ras must activate the same signaling pathways during tumor initiation as during tumor maintenance. We now demonstrate that, while multiple arms of oncogenic Ras signaling are required for tumor initiation, oncogenic activation of the downstream PI3K/AKT pathway is sufficient for tumor maintenance, as (1) PI3K or AKT activation maintained tumor growth upon loss of ER:Ras G12V expression even though these molecules did not activate other Ras effectors; (2) inducible expression of PTEN stopped continued tumor growth of established tumors; and (3) PI3K activation in otherwise nonmalignant cells permitted the cells to grow in a malignant fashion in established tumors. Thus, while cancers may become "addicted" to the initiating oncogene (Giuriato et al., 2004) , our experiments suggest that the full might of oncogenes is much more important to initiate tumors, and that only residual activities are essential, at least in the case of Ras, to maintain tumor growth.
Why cancer cells can lose their dependency on oncogenic Ras still remains to be resolved, but we speculate that, once a tumor microenvironment is established, tumor vasculature or stromal cells supply paracrine factors that activate Ras effector pathways (Mueller and Fusenig, 2004) . Additionally, we demonstrate that, in the absence of oncogenic Ras, the MAPK and RalGEF pathways become activated in tumor cells independently of p110-CAAX expression once a tumor is established, and that the cells depended upon these pathways for continued tumor growth. In fact, an established tumor (microenvironment) even fostered the growth of nonmalignant cells, provided the crucial PI3K/AKT pathway was activated. Perhaps, then,
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CANCER CELL : NOVEMBER 2005 similar premalignant cells generated during tumor evolution in human cancers capitalize on the tumor microenvironment and similarly grow in a parasitic fashion. Hence, a reduction in the dependency for oncogenic signals as tumors progress could lead to the expansion of cells with different levels of malignancy, possibly accounting for some of the known heterogeneity of the malignant fraction of solid tumors. Lastly, the discovery that PI3K activation was critical during tumor maintenance highlights the importance of this pathway as an anticancer target. We further distilled this pathway to activation of AKT, consistent with the observation that this pathway is commonly activated in human cancers. Importantly, these observations were extended to human cancer cell lines, suggesting that the importance of this pathway in experimental systems of tumor maintenance may apply to actual human cancers. Since cancers are treated at the tumor maintenance stage, targeting this aspect of Ras oncogenesis may hold promise as an approach to the management of Ras-driven human cancers.
mice were supplied with water containing 1 mg/ml of dox hydrochloride (Sigma) or injected with 4-OHT as above after tumors reached a diameter of 0.7 cm (unless otherwise specified). Four or more mice were used per treatment group in all experiments except when noted.
H&E staining, Ki67 immunohistochemistry (α-Ki67 antibody; Vector Laboratories), and the TUNEL assay (Apoptag+ Peroxidase in situ Detection Kit; Chemicon International) were performed on the indicated tumor sections using standard assays. For mixing experiments, 9 × 10 6 Ras
G12V
-TtH cells were mixed with 9 × 10 6 TtH cells expressing LacZ and p110-CAAX, ⌬Raf22W, Rlf-CAAX, or no transgene (vector) and similarly injected into the flanks of four mice. Once tumors were established, two tumors were treated with X-gal using standard protocols to identify LacZ-positive cells. The two other tumors were established in culture under G418 selection, the resulting cell culture was stained with X-gal, and strongly positive blue cells were counted.
In cases where tumor-derived cells were retested for tumor growth, tumors were established in culture under puromycin selection to enrich for TtH cells, except in the case of mixing experiments, in which cells were selected under G418. The latter cells were also subjected to another round of puromycin selection to specifically select LacZ + p110-CAAX TtH cells. Cells were injected and assayed for tumor growth as described above. Experimental procedures involving mice were reviewed and approved by the Duke University Institutional Animal Care and Use Committee.
Molecular analysis
The described Ras proteins, ⌬Raf22W, myr-AKT-HA or HA-Rlf-CAAX or HARac
Q61L
, PTEN or PTEN:ER, actin, endogenous and ectopic K-Ras, FLAG-MEK
DN
:ER, and RalA were detected by standard immunoblot analysis using the primary antibodies α-Pan-Ras (Oncogene), α-Raf-1 (Santa Cruz), α-HA (Roche), α-PTEN (Cell Signaling Technology), α-actin (Santa Cruz), α-K-Ras (Santa Cruz), α-FLAG (Sigma), and α-RalA (Transduction Laboratories), respectively. p110-CAAX mRNA was detected by reverse transcription PCR amplification, as previously described (Hamad et al., 2002) . MAPK, PI3K, and RalA pathway activation was determined by culturing cells in 0.5% fetal bovine serum for 48 hr in the presence or absence of 1 M 4-OHT (Sigma). Derived cell lysates were immunoblotted as previously described (Hamad et al., 2002) to detect AKT or the activated S473 phosphorylated form, or ERK1/2 or the activated Thr202/Tyr204 phosphorylated forms, using the primary antibodies α-Akt, α-phospho(Ser 473)-Akt (Cell Signaling Technology), K-23 α-ERK1/2 (Santa Cruz), and E10 α-phospho(Thr202/Tyr204)-p42/ 44 MAPK (Cell Signaling Technology), respectively, or to detect Ral-GTP, RalA captured with bacterially expressed GST-RalBD of RalBP1 followed by immunoblot analysis with the aforementioned RalA antibody, respectively, as previously described (Wolthuis et al., 1998) .
